Who are NGX-4010, 8% capsaicin patch's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cannabidiol Oral Product, Capsaicin 8%, Capsaicin Topical Cream, Qutenza Patch, Potassium Nitrate 2%, Hemp.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ngx-4010-8-capsaicin-patch.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NGX-4010, 8% capsaicin patch — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NGX-4010, 8% capsaicin patch (NGX-4010, 8% capsaicin patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical analgesic. Area: Pain management.

phase 3 Topical analgesic TRPV1 Pain management Small molecule Live · refreshed every 30 min

Target snapshot

NGX-4010, 8% capsaicin patch (NGX-4010, 8% capsaicin patch) — NeurogesX. NGX-4010, an 8% capsaicin patch, works by activating TRPV1 receptors to reduce pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NGX-4010, 8% capsaicin patch TARGET	NGX-4010, 8% capsaicin patch	NeurogesX	phase 3	Topical analgesic	TRPV1
Cannabidiol Oral Product	Cannabidiol Oral Product	University of Connecticut	marketed	Cannabinoid	Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel
Capsaicin 8%	Capsaicin 8%	Averitas Pharma, Inc.	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Capsaicin Topical Cream	Capsaicin Topical Cream	Women and Infants Hospital of Rhode Island	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Qutenza Patch	Qutenza Patch	M.D. Anderson Cancer Center	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Potassium Nitrate 2%	Potassium Nitrate 2%	Federal University of Uberlandia	marketed	Desensitizing agent	Nitric oxide pathway; sensory nerve fibers (TRPV1)
Hemp	Hemp	Thammasat University Hospital	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical analgesic class)

Bayer · 1 drug in this class
EpiCept Corporation · 1 drug in this class
Express Specialty Pharmacy · 1 drug in this class
Georg Kägi, MD · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Henry Ford Health System · 1 drug in this class
Johnson & Johnson Consumer and Personal Products Worldwide · 1 drug in this class
NeurogesX · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NGX-4010, 8% capsaicin patch — Competitive Intelligence Brief. https://druglandscape.com/ci/ngx-4010-8-capsaicin-patch. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing